Evolus, Inc.

EOLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-4.5M
Depreciation & Amortization $218.0K
Depreciation —
Amortization —
Stock-Based Compensation $586.0K
Net Cash from Operating Activities $-13.2M
Investing Activities
Capital Expenditures $0
Business Acquisitions —
Net Cash from Investing Activities $0
Financing Activities
Dividends Paid —
Stock Repurchases —
Net Cash from Financing Activities $13.0M
Net Change in Cash $-187.0K
Free Cash Flow $-13.2M
← Newer Page 2 of 2 Older →